Trastuzumab cardiac toxicity: a problem we put our heart into

被引：11

作者：

Bregni, Giacomo ^{[1
]}

Galli, Giulia ^{[2
]}

Gevorgyan, Arpine ^{[2
]}

de Braud, Filippo ^{[2
]}

Di Cosimo, Serena ^{[2
]}

机构：

[1] IRCCS AOU San Martino IST, Med Oncol Unit 1, Largo Rosanna Benzi 10, I-16132 Genoa, Italy

[2] Fdn IRCCS, Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

来源：

TUMORI JOURNAL | 2016年 / 102卷 / 01期

关键词：

Anthracyclines; Breast cancer; Cardiotoxicity; Trastuzumab; METASTATIC BREAST-CANCER; ADJUVANT TRASTUZUMAB; INDUCED CARDIOTOXICITY; LIPOSOMAL DOXORUBICIN; PACLITAXEL; ANTIBODY; HER2; NEOADJUVANT; DYSFUNCTION; FAILURE;

D O I：

10.5301/tj.5000393

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Trastuzumab has gained a central role in the treatment of HER2-positive breast cancer, revolutionizing care in this setting. However, since the beginning of its use there have been concerns about its cardiac safety. Trastuzumab can give rise to cardiac toxicity, in some cases leading to discontinuation of treatment. Growing evidence shows that trastuzumab toxicity can be detected early or averted by means of new chemotherapy regimens using different anthracycline formulations or avoiding anthracyclines altogether. Moreover, patients in whom cardiac toxicity develops can be treated effectively and full cardiac function can be restored thanks to progress in drug management. Knowing the characteristics and proper management of trastuzumab toxicity is of paramount importance to grant patients in this setting the best available treatment.

引用

页码：1 / 5

页数：5

共 32 条

[1]

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer [J].

Baselga, J. ;

Manikhas, A. ;

Cortes, J. ;

Llombart, A. ;

Roman, L. ;

Semiglazov, V. F. ;

Byakhov, M. ;

Lokanatha, D. ;

Forenza, S. ;

Goldfarb, R. H. ;

Matera, J. ;

Azarnia, N. ;

Hudis, C. A. ;

Rozencweig, M. .

ANNALS OF ONCOLOGY, 2014, 25 (03) :592-598

[2]

Baselga J, 1998, CANCER RES, V58, P2825

[3]

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial [J].

Buzdar, Aman U. ;

Suman, Vera J. ;

Meric-Bernstam, Funda ;

Leitch, A. Marilyn ;

Ellis, Matthew J. ;

Boughey, Judy C. ;

Unzeitig, Gary ;

Royce, Melanie ;

McCall, Linda M. ;

Ewer, Michael S. ;

Hunt, Kelly K. .

LANCET ONCOLOGY, 2013, 14 (13) :1317-1325

[4]

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation [J].

Cardinale, Daniela ;

Colombo, Alessandro ;

Torrisi, Rosalba ;

Sandri, Maria T. ;

Civelli, Maurizio ;

Salvatici, Michela ;

Lamantia, Giuseppina ;

Colombo, Nicola ;

Cortinovis, Sarah ;

Dessanai, Maria A. ;

Nole, Franco ;

Veglia, Fabrizio ;

Cipolla, Carlo M. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) :3910-3916

[5]

HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].

CARTER, P ;

PRESTA, L ;

GORMAN, CM ;

RIDGWAY, JBB ;

HENNER, D ;

WONG, WLT ;

ROWLAND, AM ;

KOTTS, C ;

CARVER, ME ;

SHEPARD, HM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289

[6]

AKT signalling in the failing heart [J].

Chaanine, Antoine H. ;

Hajjar, Roger J. .

EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (08) :825-829

[7]

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know [J].

Ewer, Michael S. ;

Ewer, Steven M. .

NATURE REVIEWS CARDIOLOGY, 2010, 7 (10) :564-575

[8]

Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer [J].

Ezaz, Ghideon ;

Long, Jessica B. ;

Gross, Cary P. ;

Chen, Jersey .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2014, 3 (01) :e000472

[9]

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors [J].

Farolfi, Alberto ;

Melegari, Elisabetta ;

Aquilina, Michele ;

Scarpi, Emanuela ;

Ibrahim, Toni ;

Maltoni, Roberta ;

Sarti, Samanta ;

Cecconetto, Lorenzo ;

Pietri, Elisabetta ;

Ferrario, Cristiano ;

Fedeli, Anna ;

Faedi, Marina ;

Nanni, Oriana ;

Frassineti, Giovanni Luca ;

Amadori, Dino ;

Rocca, Andrea .

HEART, 2013, 99 (09) :634-639

[10]

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort [J].

Gianni, Luca ;

Eiermann, Wolfgang ;

Semiglazov, Vladimir ;

Lluch, Ana ;

Tjulandin, Sergei ;

Zambetti, Milvia ;

Moliterni, Angela ;

Vazquez, Federico ;

Byakhov, Mikhail J. ;

Lichinitser, Mikhail ;

Climent, Miguel Angel ;

Ciruelos, Eva ;

Ojeda, Belen ;

Mansutti, Mauro ;

Bozhok, Alla ;

Magazzu, Domenico ;

Heinzmann, Dominik ;

Steinseifer, Jutta ;

Valagussa, Pinuccia ;

Baselga, Jose .

LANCET ONCOLOGY, 2014, 15 (06) :640-647

← 1 2 3 4 →